Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico Hypothesis
BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for COVID-19 disease which is known to have a broad clinical spectrum, from asymptomatic to critical presentation leading to death. Many researchers have investigated the factors impacting the course of the disease...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.909660/full |
| _version_ | 1828336917069955072 |
|---|---|
| author | Mariem Gdoura Mariem Gdoura Mariem Gdoura Raoua Touati Raoua Touati Sana Kalthoum Rania Ben Slama Rania Ben Slama Nouel Fatnassi Nouel Fatnassi Mehdi Mrad Lamia Ammari Lamia Ammari Nozha Brahmi Amira Ben Jazia Nahed Hogga Nahed Hogga Henda Triki Henda Triki Sondes Haddad-Boubaker Sondes Haddad-Boubaker |
| author_facet | Mariem Gdoura Mariem Gdoura Mariem Gdoura Raoua Touati Raoua Touati Sana Kalthoum Rania Ben Slama Rania Ben Slama Nouel Fatnassi Nouel Fatnassi Mehdi Mrad Lamia Ammari Lamia Ammari Nozha Brahmi Amira Ben Jazia Nahed Hogga Nahed Hogga Henda Triki Henda Triki Sondes Haddad-Boubaker Sondes Haddad-Boubaker |
| author_sort | Mariem Gdoura |
| collection | DOAJ |
| description | BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for COVID-19 disease which is known to have a broad clinical spectrum, from asymptomatic to critical presentation leading to death. Many researchers have investigated the factors impacting the course of the disease. Our previous in silico study suggested a possible protective effect of Hepatitis B, Tetanus and Measles vaccines against COVID-19. In continuity, we conducted a cross-sectional clinical study in order to confirm our in silico assumptions regarding the HBs-Ag antibodies.MethodsA representative sex- and age-matched sample of patients with confirmed COVID-19 was selected (n = 340). All clinical presentations were equally represented. Using an ELISA test, each patient benefited of a serology for the detection and measurement of the anti-HBs specific IgG antibodies. The obtained results allowed determining the different correlations between these antibody titers and the disease severity. The R® software and the MedCalc® software served to calculate the Spearman's coefficient of rank correlation (rho) for the obtained titers per severity group as well as the different other calculations and figure representations.ResultsA significant positive correlation was found with the anti-HBs titers (rho = 0.107; p = 0.04). High anti-HBs titers were significantly associated with the mild presentation of COVID-19. A significant difference was found between the obtained titers per severity class (chi-2 test, p = 0.03).Discussion/ConclusionOur findings demonstrated that anti-HBs titers were significantly higher for patients having mild COVID-19 presentations. We presume that being immunized against the HB may play a protective role in the course of the disease. Our study provided more key elements in understanding the disparity of the clinical spectrum among regions. |
| first_indexed | 2024-04-13T22:07:54Z |
| format | Article |
| id | doaj.art-3e260408cc7447508523574e61825357 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-13T22:07:54Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-3e260408cc7447508523574e618253572022-12-22T02:27:51ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-07-01910.3389/fmed.2022.909660909660Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico HypothesisMariem Gdoura0Mariem Gdoura1Mariem Gdoura2Raoua Touati3Raoua Touati4Sana Kalthoum5Rania Ben Slama6Rania Ben Slama7Nouel Fatnassi8Nouel Fatnassi9Mehdi Mrad10Lamia Ammari11Lamia Ammari12Nozha Brahmi13Amira Ben Jazia14Nahed Hogga15Nahed Hogga16Henda Triki17Henda Triki18Sondes Haddad-Boubaker19Sondes Haddad-Boubaker20Laboratory of Clinical Virology, WHO Regional Reference Laboratory for Poliomyelitis and Measles for the EMR, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaLR20IPT10 Laboratory of Virus, Host and Vectors, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaDepartment of Clinical Biology, Faculty of Pharmacy of Monastir, University of Monastir, Monastir, TunisiaLaboratory of Clinical Virology, WHO Regional Reference Laboratory for Poliomyelitis and Measles for the EMR, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaLR20IPT10 Laboratory of Virus, Host and Vectors, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaCentre National de Veille Zoosanitaire, Tunis, TunisiaLaboratory of Clinical Virology, WHO Regional Reference Laboratory for Poliomyelitis and Measles for the EMR, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaLR20IPT10 Laboratory of Virus, Host and Vectors, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaLR20IPT10 Laboratory of Virus, Host and Vectors, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaCentre National de Veille Zoosanitaire, Tunis, TunisiaLaboratory of Biochemistry, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaLR20IPT10 Laboratory of Virus, Host and Vectors, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaInfectious Diseases Departement, Rabta Hospital, Tunis, TunisiaIntensive Care Service, Emergence Medical Assistance Center, Tunis, TunisiaIntensive Care Service, Emergence Medical Assistance Center, Tunis, TunisiaLaboratory of Clinical Virology, WHO Regional Reference Laboratory for Poliomyelitis and Measles for the EMR, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaLR20IPT10 Laboratory of Virus, Host and Vectors, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaLaboratory of Clinical Virology, WHO Regional Reference Laboratory for Poliomyelitis and Measles for the EMR, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaLR20IPT10 Laboratory of Virus, Host and Vectors, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaLaboratory of Clinical Virology, WHO Regional Reference Laboratory for Poliomyelitis and Measles for the EMR, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaLR20IPT10 Laboratory of Virus, Host and Vectors, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, TunisiaBackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for COVID-19 disease which is known to have a broad clinical spectrum, from asymptomatic to critical presentation leading to death. Many researchers have investigated the factors impacting the course of the disease. Our previous in silico study suggested a possible protective effect of Hepatitis B, Tetanus and Measles vaccines against COVID-19. In continuity, we conducted a cross-sectional clinical study in order to confirm our in silico assumptions regarding the HBs-Ag antibodies.MethodsA representative sex- and age-matched sample of patients with confirmed COVID-19 was selected (n = 340). All clinical presentations were equally represented. Using an ELISA test, each patient benefited of a serology for the detection and measurement of the anti-HBs specific IgG antibodies. The obtained results allowed determining the different correlations between these antibody titers and the disease severity. The R® software and the MedCalc® software served to calculate the Spearman's coefficient of rank correlation (rho) for the obtained titers per severity group as well as the different other calculations and figure representations.ResultsA significant positive correlation was found with the anti-HBs titers (rho = 0.107; p = 0.04). High anti-HBs titers were significantly associated with the mild presentation of COVID-19. A significant difference was found between the obtained titers per severity class (chi-2 test, p = 0.03).Discussion/ConclusionOur findings demonstrated that anti-HBs titers were significantly higher for patients having mild COVID-19 presentations. We presume that being immunized against the HB may play a protective role in the course of the disease. Our study provided more key elements in understanding the disparity of the clinical spectrum among regions.https://www.frontiersin.org/articles/10.3389/fmed.2022.909660/fullCOVID-19correlationantibody titerHepatitis BSARS-CoV-2 |
| spellingShingle | Mariem Gdoura Mariem Gdoura Mariem Gdoura Raoua Touati Raoua Touati Sana Kalthoum Rania Ben Slama Rania Ben Slama Nouel Fatnassi Nouel Fatnassi Mehdi Mrad Lamia Ammari Lamia Ammari Nozha Brahmi Amira Ben Jazia Nahed Hogga Nahed Hogga Henda Triki Henda Triki Sondes Haddad-Boubaker Sondes Haddad-Boubaker Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico Hypothesis Frontiers in Medicine COVID-19 correlation antibody titer Hepatitis B SARS-CoV-2 |
| title | Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico Hypothesis |
| title_full | Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico Hypothesis |
| title_fullStr | Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico Hypothesis |
| title_full_unstemmed | Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico Hypothesis |
| title_short | Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study Confirming in silico Hypothesis |
| title_sort | presumed protective role for anti hepatitis b virus antibodies against covid 19 severe cases a clinical study confirming in silico hypothesis |
| topic | COVID-19 correlation antibody titer Hepatitis B SARS-CoV-2 |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.909660/full |
| work_keys_str_mv | AT mariemgdoura presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT mariemgdoura presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT mariemgdoura presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT raouatouati presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT raouatouati presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT sanakalthoum presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT raniabenslama presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT raniabenslama presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT nouelfatnassi presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT nouelfatnassi presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT mehdimrad presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT lamiaammari presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT lamiaammari presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT nozhabrahmi presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT amirabenjazia presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT nahedhogga presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT nahedhogga presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT hendatriki presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT hendatriki presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT sondeshaddadboubaker presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis AT sondeshaddadboubaker presumedprotectiveroleforantihepatitisbvirusantibodiesagainstcovid19severecasesaclinicalstudyconfirminginsilicohypothesis |